There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lyra Therapeutics (LYRA – Research Report), Omega Therapeutics (OMGA – Research Report) and Biora Therapeutics (BIOR – Research Report) with bullish sentiments.
Omega Therapeutics (OMGA)
In a report issued on September 27, Keay Nakae from Chardan Capital reiterated a Buy rating on Omega Therapeutics, with a price target of $12.00. The company’s shares closed last Friday at $2.15, close to its 52-week low of $2.11.
According to TipRanks.com, Nakae is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Omega Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.80, implying a 408.6% upside from current levels. In a report issued on September 26, Jefferies also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LYRA:
- Lyra Therapeutics price target raised to $15 from $13 at BofA
- Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
- Lyra Therapeutics announces results from BEACON Phase 2 study of LYR-220
- Lyra Therapeutics to Participate in Upcoming Investor Conferences
- Lyra Therapeutics initiated with a Buy at H.C. Wainwright
